The group with a low H4Mscore had a greater proportion of patients who responded to anti-PD-1 and anti-CTLA4 immunotherapy, and the H4Mscore was higher in nonresponding HCC patients (Fig. 7D–E). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.